125 related articles for article (PubMed ID: 38252427)
1. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma.
Lim-Fat MJ; Iorgulescu JB; Rahman R; Bhave V; Muzikansky A; Woodward E; Whorral S; Allen M; Touat M; Li X; Xy G; Patel J; Gerstner ER; Kalpathy-Cramer J; Youssef G; Chukwueke U; McFaline-Figueroa JR; Nayak L; Lee EQ; Reardon DA; Beroukhim R; Huang RY; Bi WL; Ligon KL; Wen PY
Clin Cancer Res; 2024 Apr; 30(7):1327-1337. PubMed ID: 38252427
[TBL] [Abstract][Full Text] [Related]
2. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
[TBL] [Abstract][Full Text] [Related]
3. Molecular characteristics and clinical features of multifocal glioblastoma.
Dono A; Wang E; Lopez-Rivera V; Ramesh AV; Tandon N; Ballester LY; Esquenazi Y
J Neurooncol; 2020 Jun; 148(2):389-397. PubMed ID: 32440969
[TBL] [Abstract][Full Text] [Related]
4. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
Armocida D; Pesce A; Frati A; Santoro A; Salvati M
J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
[TBL] [Abstract][Full Text] [Related]
5. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.
Barresi V; Simbolo M; Mafficini A; Martini M; Calicchia M; Piredda ML; Ciaparrone C; Bonizzato G; Ammendola S; Caffo M; Pinna G; Sala F; Lawlor RT; Ghimenton C; Scarpa A
Acta Neuropathol Commun; 2021 Dec; 9(1):200. PubMed ID: 34952640
[TBL] [Abstract][Full Text] [Related]
6. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
7. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
Abou Alaiwi S; Nassar AH; Xie W; Bakouny Z; Berchuck JE; Braun DA; Baca SC; Nuzzo PV; Flippot R; Mouhieddine TH; Spurr LF; Li YY; Li T; Flaifel A; Steinharter JA; Margolis CA; Vokes NI; Du H; Shukla SA; Cherniack AD; Sonpavde G; Haddad RI; Awad MM; Giannakis M; Hodi FS; Liu XS; Signoretti S; Kadoch C; Freedman ML; Kwiatkowski DJ; Van Allen EM; Choueiri TK
Cancer Immunol Res; 2020 Aug; 8(8):1075-1084. PubMed ID: 32321774
[TBL] [Abstract][Full Text] [Related]
8. MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma.
Li G; Ma L; Feng C; Yin H; Bao J; Wu D; Zhang Z; Li X; Li Z; Yang C; Wang H; Fang F; Hu X; Li M; Xu L; Xu Y; Liang H; Yang T; Wang J; Pan J
BMC Cancer; 2024 Feb; 24(1):220. PubMed ID: 38365636
[TBL] [Abstract][Full Text] [Related]
9. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.
Higa N; Akahane T; Hamada T; Yonezawa H; Uchida H; Makino R; Watanabe S; Takajo T; Yokoyama S; Kirishima M; Matsuo K; Fujio S; Hanaya R; Tanimoto A; Yoshimoto K
Cancer Med; 2023 Jan; 12(1):49-60. PubMed ID: 35695190
[TBL] [Abstract][Full Text] [Related]
10. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma.
Diamandis P; Ferrer-Luna R; Huang RY; Folkerth RD; Ligon AH; Wen PY; Beroukhim R; Ligon KL; Ramkissoon SH
Diagn Pathol; 2016 Jan; 11():13. PubMed ID: 26817999
[TBL] [Abstract][Full Text] [Related]
12. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
13. Brahma-Related Gene-1 (BRG1) promotes the malignant phenotype of glioblastoma cells.
Wang Y; Yang CH; Schultz AP; Sims MM; Miller DD; Pfeffer LM
J Cell Mol Med; 2021 Mar; 25(6):2956-2966. PubMed ID: 33528916
[TBL] [Abstract][Full Text] [Related]
14. Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma.
Stasik S; Juratli TA; Petzold A; Richter S; Zolal A; Schackert G; Dahl A; Krex D; Thiede C
Neoplasia; 2020 Dec; 22(12):800-808. PubMed ID: 33142244
[TBL] [Abstract][Full Text] [Related]
15. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.
Liu Q; Liu Y; Li W; Wang X; Sawaya R; Lang FF; Yung WK; Chen K; Fuller GN; Zhang W
Acta Neuropathol; 2015 Oct; 130(4):587-97. PubMed ID: 26323991
[TBL] [Abstract][Full Text] [Related]
16. BET bromodomain proteins are required for glioblastoma cell proliferation.
Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
[TBL] [Abstract][Full Text] [Related]
17. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
[TBL] [Abstract][Full Text] [Related]
18. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A
Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121
[TBL] [Abstract][Full Text] [Related]
19. The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
Velázquez Vega JE; Brat DJ; Ryken TC; Olson JJ
J Neurooncol; 2020 Nov; 150(2):143-164. PubMed ID: 33215342
[TBL] [Abstract][Full Text] [Related]
20. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
